Phase II, multi-center, open-label, single-arm clinical trial evaluating the efficacy and safety of Mycophenolate Mofetil in patients with high-grade locally advanced or metastatic osteosarcoma (ESMMO): rationale and design of the ESMMO trial
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background: Clinical outcomes of patients with osteosarcoma remain unsatisfactory, with little improvement in a 5-year overall survival over the past three decades. There is a substantial need for further research and development to identify and develop more efficacious agents/regimens in order to improve clinical outcomes of patients for whom the prognosis is unfavorable. Recently, mycophenolate mofetil, a prodrug of mycophenolic acid, has been found to have anticancer activity against osteosarcoma in both in vitro and animal experiments, so that further investigation in humans is warranted. Methods: A total of 27 patients with high-grade locally advanced or metastatic osteosarcoma will be enrolled into this phase II, multi-center, open-label, single-arm, two-stage clinical trial. The main objectives of this study are to determine the efficacy and safety of mycophenolate mofetil in the patients. The primary endpoint is progression-free survival at 16 weeks; the secondary endpoints include progression-free survival, overall survival, overall response rate, safety parameters, pharmacokinetic parameters, biomarkers, pain score, and quality of life. Mycophenolate mofetil at the initial dose of 5 g/day or lower will be administered for 4 cycles (28 days/cycle) or until disease progression or unacceptable toxicity. The dose of mycophenolate mofetil may be reduced by 1–2 g/day or withheld for some Grade 3 or Grade 4 toxicities whenever clinically needed. The duration of study participation is approximately 4–5 months, with a minimum of 12 study visits. If mycophenolate mofetil proves beneficial to some patients, as evidenced by stable disease or partial response at 16 weeks, administration of mycophenolate mofetil will continue in the extension period. Discussion: This trial is the first step in the translation of therapeutic potential of mycophenolate mofetil emerging from in vitro and animal studies into the clinical domain. It is designed to assess the efficacy and safety of mycophenolate mofetil in patients with high-grade locally advanced or metastatic osteosarcoma. The results will provide important information about whether or not mycophenolate mofetil is worth further development. Trial registration: This trial was prospectively registered on Thai Clinical Trials Registry (registration number:TCTR20190701001). The posted information will be updated as needed to reflect protocol amendments and study progress.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RECIST 1.1—Update and clarification: From the RECIST committee
Schwartz, L. H., Litière, S., de Vries, E., Ford, R., Gwyther, S., Mandrekar, S., Shankar, L., Bogaerts, J., Chen, A., Dancey, J., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.03.081 · Cited by 1,906
Mirabello, L., Troisi, R. J., & Savage, S. A. (2009) · International Journal of Cancer · doi:10.1002/ijc.24320 · Cited by 791
Kempf-Bielack, B., Bielack, S. S., Jürgens, H., Branscheid, D., Berdel, W. E., Exner, G. U., Göbel, U., Helmke, K., Jundt, G., Kabisch, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.063 · Cited by 643
Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?
Anninga, J. K., Gelderblom, H., Fiocco, M., Kroep, J. R., Taminiau, A. H. M., Hogendoorn, P. C. W., & Egeler, R. M. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.05.030 · Cited by 456
Postrelapse Survival in Osteosarcoma of the Extremities: Prognostic Factors for Long-Term Survival
Ferrari, S., Briccoli, A., Mercuri, M., Bertoni, F., Picci, P., Tienghi, A., Del Prever, A. B., Fagioli, F., Comandone, A., & Bacci, G. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.141 · Cited by 316
Lagmay, J. P., Krailo, M. D., Dang, H., Kim, A., Hawkins, D. S., Beaty, O., Widemann, B. C., Zwerdling, T., Bomgaars, L., Langevin, A.-M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.5381 · Cited by 190
Leary, S. E. S., Wozniak, A. W., Billups, C. A., Wu, J., McPherson, V., Neel, M. D., Rao, B. N., & Daw, N. C. (2013) · Cancer · doi:10.1002/cncr.28111 · Cited by 129
Cited by
Aran, V., Devalle, S., Meohas, W., Heringer, M., Cunha Caruso, A., Pinheiro Aguiar, D., Leite Duarte, M. E., & Moura Neto, V. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103340 · Cited by 87
Gaspar, N., Campbell-Hewson, Q., Gallego Melcon, S., Locatelli, F., Venkatramani, R., Hecker-Nolting, S., Gambart, M., Bautista, F., Thebaud, E., Aerts, I., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100250 · Cited by 59
van Ewijk, R., Cleirec, M., Herold, N., le Deley, M.-C., van Eijkelenburg, N., Boudou-Rouquette, P., Risbourg, S., Strauss, S. J., Palmerini, E., Boye, K., et al. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102625 · Cited by 19
Gaspar, N., Campbell-Hewson, Q., Huang, J., Okpara, C. E., & Bautista, F. (2021) · Future Oncology · doi:10.2217/fon-2021-0743 · Cited by 9
Metadata
- Authors
- Koonrungsesomboon, N., Ngamphaiboon, N., Townamchai, N., Teeyakasem, P., Charoentum, C., Charoenkwan, P., Natesirinilkul, R., Sathitsamitphong, L., Ativitavas, T., Chaiyawat, P., Klangjorhor, J., Hongeng, S., & Pruksakorn, D.
- Venue
- BMC Cancer
- Published
- 2020-03-30
- Volume
- 20
- Issue
- 1
- Pages
- 268-268
- ISSN
- 1471-2407 (ISSN-L)
- OpenAlex
- W3013902201
- Cited by
- 18
- References
- 7
- FWCI
- 1.72
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase II, multi-center, open-label, single-arm clinical trial evaluating the efficacy and safety of Mycophenolate Mofetil in patients with high-grade locally advanced or metastatic osteosarcoma (ESMMO): rationale and design of the ESMMO trial. https://app.cochat.ai/papers/10.1186/s12885-020-06751-2
- The paper
- Koonrungsesomboon, N., Ngamphaiboon, N., Townamchai, N., Teeyakasem, P., Charoentum, C., Charoenkwan, P., Natesirinilkul, R., Sathitsamitphong, L., Ativitavas, T., Chaiyawat, P., Klangjorhor, J., Hongeng, S., & Pruksakorn, D. (2020). Phase II, multi-center, open-label, single-arm clinical trial evaluating the efficacy and safety of Mycophenolate Mofetil in patients with high-grade locally advanced or metastatic osteosarcoma (ESMMO): rationale and design of the ESMMO trial. BMC Cancer. https://doi.org/10.1186/s12885-020-06751-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.